[1] Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997;120:1485–508. [23]
[2] Mosser J, Douar A-M, Sarde C-O et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993;361:726–30. [24]
[3] Sarde C-O, Mosser J, Kioschis P et al. Genomic organization of the
adrenoleukodystrophy gene. Genomics 1994;22:13–20.
[4] Moser HW, Moser AB, Naidu S et al. Clinical aspects of adreno- [25]
leukodystrophy and adrenomyeloneuropathy. Dev Neurosci
1991;13:254–61.
[5] Moser HW, Moser AB, Frayer KK et al. Adrenoleukodystrophy: [26]
Increased plasma content of saturated very long chain fatty acids.
Neurology 1981;31:1241–9.
[6] Aubourg P, Adamsbaum C, Lavallard-Rousseau M-C et al. A twoyear trial of oleic and erucic acids (`Lorenzo's oil') as treatment for [27]
adrenoleukomyelopathy. New Eng J Med 1993;329:745–52.
Miike T, Taku K, Tamura T et al. Clinical improvement of
